Acute peripheral metabolic effects of intraarterial ghrelin infusion in healthy young men

What Was Tested

The paper reports a study of Ghrelin, published as a randomized controlled trial.

To investigate whether these effects are mediated directly by ghrelin in skeletal muscle tissue.

Why It Was Studied

Ghrelin is the endogenous agonist for the growth hormone secretagogue receptor (GHS-R).

Who Took Part

The age groups tagged for this paper are young adults and adults, men only.

Eight healthy men (25.5 ± 3.1 years) received 240 min of intraarterial ghrelin infusion (4.2 ng × kg(-1) × min(-1)) into one femoral artery and intraarterial placebo infusion into the contralateral artery.

How the Study Was Run

The design is described as randomized, single-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Ghrelin and who got the comparison, which limits bias.

Only one side, usually the participants, was kept unaware of whether Ghrelin was given.

Some participants received a placebo instead of Ghrelin, giving a reference point.

This study was single blinded, randomized, and placebo controlled.

Simultaneous blood samples were drawn from both femoral veins and muscle biopsies were obtained from both legs during both a basal period and during a hyperinsulinemic and euglycemic clamp period.

What Was Measured

The subject headings attached to it are Coloring Agents, Fatty Acids, Nonesterified, Femoral Artery, Ghrelin, Glucose, Glucose Clamp Technique and Indocyanine Green.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Ghrelin.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Ghrelin compound page, all human trials.